Drug intelligence / Profile preview

interleukin-2 + methotrexate

Development stage: Unknown
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous

Overview

A combination therapy consisting of low-dose interleukin-2 (IL-2) and methotrexate (MTX) used primarily for the treatment of rheumatoid arthritis (RA). This combination has shown superior efficacy compared to MTX alone in clinical outcomes including CDAI, SDAI, and ACR response. Low-dose IL-2 works by increasing regulatory T cells (Tregs), which helps maintain immune balance, while MTX has anti-inflammatory effects related to interruption of adenosine and other inflammatory pathways. The combination therapy has demonstrated significant reductions in inflammatory cytokines, including IL-17A, IFN-γ, TNF-α, and IL-12 levels.

Other names: Ld-IL2 + MTXlow-dose interleukin-2 + methotrexate

Targets

DHFR (Dihydrofolate reductase)IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on interleukin-2 + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interleukin-2 + methotrexate.

Explore the full profile